PBAC's latest decision on Iron (as sucrose): Recommended with restriction (2014). Considered for Iron deficiency anaemia in patients undergoing chronic haemodialysis receiving supplemental erythropoietin therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Patients undergoing chronic haemodialysis receiving erythropoiesis stimulating agent therapy, with documented hypersensitivity reaction to iron polymaltose (restricted benefit) or any patient meeting the unrestricted benefit criteria.
Therapy area
Haematology
Line of therapy
Second-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
iron polymaltose
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no numeric ICER calculated.